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ABSTRACT
The cornea remains in a state of deturgescence,
maintained by endothelial cell Na?/K? ATPase
and by tight junctions between endothelial cells
that limit entrance of fluid into the stroma.
Fuchs’ endothelial corneal dystrophy (FECD)
was initially described by Fuchs in 1910 as a
combination of epithelial and stromal edema in
older patients. It manifests as bilateral, albeit
asymmetric, central corneal guttae, corneal
edema, and reduced vision. When edema is
severe, the corneal epithelium can detach from
its basement membrane, creating painful bullae
on the anterior surface of the cornea. The course
of this dystrophy can be further accelerated
after intraocular surgery, specifically cataract
extraction. Pseudophakic bullous keratopathy
(PBK) is endothelial cell loss caused by surgery
in the anterior chamber. If the corneal
endothelium is damaged during surgery, the
same spectrum of symptoms as found in FECD
can develop. In the nineteenth century,
penetrating keratoplasty was the only surgical
procedure available for isolated endothelial
disease. In the 1960s, Dr. Jose´ Barraquer
described a method of endothelial keratoplasty
using an anterior approach via laser-assisted
in situ keratomileusis (LASIK) flap. In 1999,
Melles and colleague described their technique
of posterior lamellar keratoplasty. Later, Melles
et al. started to change host dissection using
simple ‘‘descemetorhexis’’ in a procedure
known as Descemet’s stripping endothelial
keratoplasty. Following the widespread
adoption of Descemet’s stripping automated
endothelial keratoplasty, the Melles group
revisited selective Descemet’s membrane
transplantation and reported the results of a
new procedure, Descemet’s membrane
endothelial keratoplasty (DMEK). Recently,
some eye banks have experimented with the
preparation of DMEK/Descemet’s membrane
automated endothelial keratoplasty donor
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tissue that may help the surgeon avoid the risk
of tissue loss during the stromal separation step.
Recently, the authors described a new bimanual
technique for insertion and positioning of
endothelium–Descemet membrane grafts in
DMEK.
Keywords: Endothelial; Disease; Endothelial
transplant; Fuch’s dystrophy; Ocular surgery;
Ophthalmology; Posterior lamellar
keratoplasty; Pseudophakic bullous edema
INTRODUCTION
The adult human cornea averages 540 lm in
thickness [1], with the following layers from
anterior to posterior: epithelium, Bowman’s
membrane, stroma, Descemet’s membrane
(DM), and endothelium. The cornea remains
in a state of deturgescence, maintained by
endothelial cell Na?/K? ATPase and by tight
junctions between endothelial cells that limit
entrance of fluid into the stroma. By
maintaining an optimum level of corneal
hydration, endothelial cells preserve the
ordered arrangement of collagen, which is
crucial for corneal transparency [2]. When
endothelial cell density is low, the loss of tight
junctions between cells allows more fluid to
enter the stroma. The endothelial cells that
remain may have a higher concentration of
Na?/K? ATPase in an effort to compensate for
the loss [1].
The average human cornea has an
endothelial cell density of 5,000–6,000 cells/
mm2 at birth, decreasing to 2,500–3,000 cells/
mm2 by adulthood. There is an average cell loss
of 0.6% per year [1]. Corneal edema appears at
700–400 cells/mm2 [1, 3]. Adult human corneal
endothelial cells are arrested in the G phase of
the cell cycle and do not undergo mitosis [4].
Therefore, lost cells cannot be replaced
physiologically.
This review follows the development of
surgical treatment of endothelial diseases, from
penetrating keratoplasty to different approaches
of selective endothelial keratoplasty.
METHODS
For this review, the authors searched PubMed
using the keywords ‘‘Endothelial disease;
Endothelial transplant; Fuch’s dystrophy;
Ocular surgery; Posterior lamellar keratoplasty;
Pseudophakic bullous edema’’. They also
searched ophthalmology books about cornea
and papers published in the last decades
discussing the different steps of evolution of
corneal surgeries and management of
endothelial diseases. The article is divided to
subsequent headlines putting into consideration
the chronological evolution (abstract,
introduction, methods, indications for
keratoplasty, keratoplasty in the nineteenth
century, keratoplasty in the early twentieth
century, use of the human cornea, fixation
techniques, establishment of eye banks,
development of endothelial keratoplasty,
conclusion and references). The authors used
the statistics of the eye bank association of
America. The abstract, the full article and
references were obtained and references checked
for additional material where appropriate.
INDICATIONS FOR KERATOPLASTY
Fuchs’ endothelial corneal dystrophy (FECD)
was initially described by Fuchs [5] in 1910 as a
combination of epithelial and stromal edema in
older patients. It manifests itself as bilateral,
albeit asymmetric, central corneal guttae,
corneal edema, and reduced vision [6, 7]. The
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DM thickens and develops excrescences known
histopathologically as guttae. Stromal edema
develops and corneal thickness may increase to
over 1,000 lm. When the edema is severe, the
corneal epithelium can detach from its basement
membrane, creating painful bullae on the
anterior surface of the cornea [2, 8]. FECD is the
most common endothelial dystrophy and is
usually seen beyond the fifth decade of life,
although not all cases are in the elderly; Biswas
et al. [9] reported several families with early onset
of this dystrophy in the third and fourth decades
of life. FECD is, despite its dominant inheritance
form, more common and progressive in women
[10]. It may also present in a sporadic form and is
thought to be a primary disorder of the
endothelium. The total number of endothelial
cells is low and existing cells may not function
properly. The course of this dystrophy can be
further accelerated after intraocular surgery,
specifically cataract extraction. A cell count of
less than 1,000 cells/mm2 or corneal thickness
greater than 640 lm are considered major risk
factors for corneal decompensation after cataract
surgery [11–13].
Pseudophakic bullous keratopathy (PBK) is a
term used to describe endothelial cell loss caused
by surgery in the anterior chamber. If the corneal
endothelium is damaged during surgery (as often
occurs during cataract extraction) [3], the same
spectrum of symptoms as found in FECD can
develop, although the histological phenotype of
both diseases is different and there is no guttata in
PBK (Fig. 1).
Toxic anterior segment syndrome (TASS) is a
rare complication of intraocular surgery that
has only recently been recognized [14]. It is an
acute sterile inflammation in the anterior
segment caused by noxious agents such as
medications, residual viscoelastic agents, and
preservatives, or by an altered osmolarity or pH
of the irrigating solution [15–17]. Permanent
corneal endothelial damage can occur in severe
cases of TASS.
KERATOPLASTY
IN THE NINETEENTH CENTURY
In the nineteenth century, penetrating
keratoplasty (PK) was the only surgical
procedure used for isolated endothelial disease
whether it was FECD or PBK; however, this
procedure proved unsuccessful because of a
total lack of knowledge about many basic
concepts that could prevent failure, such as
sepsis, immunology and tissue biology,
anatomy and physiology of the cornea, and
anesthesia.
Fig. 1 Corneal edema in a pseudophakic eye with Fuchs’ endothelial corneal dystrophy
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The concept of removing a cloudy cornea
was discussed by Charles Darwin’s
grandfather, Erasmus Darwin, in 1796. He
felt that after an ulcer of the cornea, the scar
could be cut out and have it heal with a
transparent scar [18]. In 1824, Franz Reisinger
[19] coined the term ‘keratoplasty’ and he is
credited with this term, although controversy
surrounds this attribution. During this period,
it was believed that the human cornea could
be replaced with an animal cornea from
another species. Wilhelmus Thome, in 1834,
was the first to use the term ‘corneal
transplantation’, although he did not
undertake such a procedure [18]. Records
suggest that the first successful transplant
was performed by James Bigger, who, when
captured by Saharan Bedouins, was able to
achieve his freedom by transplanting the
opaque cornea of the pet gazelle belonging
to the head sheik using another gazelle’s
cornea [20]. Kissam [21], in 1844, discussed
guidelines for keratoplasty, which although
written many years ago are actually accurate
for current keratoplasty techniques. Kissam
suggested that the donor and recipient
should be of the same size, there should be
rapid and atraumatic transfer of donor tissue
with minimal tissue damage, and that there
should be careful corneal fixation and
protection of the intraocular contents.
Henry Power [22] recommended corneal
transplantation within the same species. In
1877, Von Hippel started publishing his
studies using circular mechanical trephines to
remove the donor and recipient corneas. This
same technique is used for keratoplasty
procedures today. Von Hippel did, however,
set back keratoplasty for a time, as he
recommended heteroplastic over homoplastic
tissue [18]. Other factors leading to successful
corneal transplantation included the
development of general anesthesia. This was
first used in 1846, in the Etherdome at
Massachusetts General Hospital, and was
followed by the introduction of chloroform in
1847. In 1867, Lister first brought attention to
the importance of an aseptic setting for
successful surgery. Topical cocaine was
discovered by Kohler in 1884 [18].
KERATOPLASTY IN THE EARLY
TWENTIETH CENTURY
The first visually successful human corneal
transplant was performed on December 7,
1905, in Olmutz, a small Moravian city near
Prague in Slovakia. It was performed by Dr.
Eduard Zirm on Alois Golgar [23], who had
bilateral blindness caused by lime injury. Both
corneas were severely scarred centrally, leaving
some peripheral clarity. His visual acuity was
hand motions in both eyes. Karl Braur, an
11-year-old boy, was the donor. He
experienced loss of vision following an
intraocular metallic foreign body injury in July
1905. Zirm enucleated the blind eye and used
the donor’s clear cornea to form two 5.0-mm
donor corneas. He removed the corneas with a
5.0-mm von Hippel trephine.
Zirm kept the transplants in place with a
bridge of conjunctiva, sutured over the corneas.
The patient’s left corneal transplant was
trephined from a more central part of Braur’s
donated cornea. The right corneal transplant
failed and had to be removed, but the left
transplant cleared and Golgar was sent home
15 weeks after the operation. A year afterward,
an ophthalmologist checked Golgar’s visual
acuity and found it to be 6/36 with a
stenopeic disc. Zirm died in March 1944
without recording any other corneal
transplants in his 45 publications.
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The majority of research into keratoplasty
was conducted in Europe. Magitot [24]
successfully used preserved corneas as early as
1911, and Elschnig [25] performed 170 corneal
transplants in his Prague clinic with 22%
success rate, and without the use of topical
antibiotics or steroids. During this time, most of
the corneal transplants were small,
approximately 4.0 mm, and were kept in place
either by conjunctival flaps, with lid closure, or
by fixation sutures placed across the cornea, as
performed by Zirm.
USE OF THE HUMAN CORNEA
In 1921, Harry Gradle [26] highlighted the
uniformly unsuccessful results for keratoplasty.
Up until this time, only single case reports had
been published and in only one instance were
two cases published [26]. None of the patients
who underwent keratoplasty had good vision
and Gradle concluded that transplantation
from another species was a biologic
impossibility (whether or not transplants
could be done successfully within the same
species was not completely agreed upon). He
did not refer to Elschnig’s work in Prague, where
corneal transplants in humans had been
performed for at least 10 years with some
modicum of success.
In England in the 1930s, Sir Tudor Thomas
[27] experimented with corneal transplantation
using rabbits’ eyes. He felt that it was premature
to operate on humans when the results were so
unsuccessful.
By the mid-1930s, when transplantation had
become more successful, there were insufficient
diseased eyes with clear corneas requiring
enucleation to satisfy the needs of the corneal
transplant surgeons, who had many bilaterally
blind patients on their lists. Elschnig supported
the use of cadaver corneas, but it was Vladimir
Filatov [28] who was primarily responsible for
popularizing the use of cadaver corneas for
corneal transplant purposes. Filatov [28], in a
review of corneal transplantation, mentioned
the use of cadaver corneas stored in an ice chest
at 4 C. The eyes were enucleated ‘within 2–3 h
before the body was taken to the morgue, or
while in the morgue, certainly within just a few
hours of death [28]. The corneas were used
within 20–56 h after death [28]. These early
techniques for cadaver enucleation are still used
today in many countries. Other corneal
surgeons preceded Filatov with individual case
reports of using cadaver corneas for corneal
transplantation, but it was Filatov who was
credited with popularizing this approach.
FIXATION TECHNIQUES
Fixation technique is important in the outcome
of corneal transplantation. Many methods have
been used to ensure the proper alignment of the
donor cornea, beginning with just conjunctival
flaps and crossed sutures over the cornea. In the
beginning only small grafts, less than 4.0 mm,
were used. With these small grafts, overlay
sutures were satisfactory for stabilization when
the suture material was equivalent to 4–0 or 5–0
silk [18].
Numerous techniques have been described
in the literature for corneal fixation [29]. Most
of these fixation techniques preceded edge-to-
edge appositional sutures. The sutures were
anchored in the sclera beyond the cornea
and were removed soon after corneal
transplantation because of loosening and
vascularization. Ramon Castroviejo’s unusual
technique of square corneal transplants created
with a parallel razorblade was utilized until the
1960s, mostly for keratoconus. He felt that a
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square graft, with one point directed toward
6 o’clock, provided better stability in
keratoconus.
Castroviejo’s [30, 31] investigations of
keratoplasty, his design of unique instruments,
and his exquisite skill almost single-handedly
improved techniques and popularized corneal
transplants in the 1940s and 1950s. Aside from
Ramon Castroviejo, few ophthalmologists in
the USA were performing corneal
transplantation, either experimentally or on
humans, before World War 2. A corneal
transplant symposium, sponsored by the
American Academy of Ophthalmology, was
held for the first time at Palmer House in
Chicago in October 1947. A panel of
physicians, including R. Townley Paton, John
M. McLean, Ramon Castroviejo, Kornblueth
and Edward Maumenee, presented at this
symposium. Paton [32] spoke about patient
selection, while McLean [33] discussed
keratoplasty technique, quoting liberally from
Castroviejo’s work, which dated back to 1932.
Castroviejo reviewed complications and the
overlay suture for fixation [34]. Complications
of keratoplasty included significant anterior
synechiae, iris prolapse, infections, glaucoma,
vascularization, inflammation, edema, and
deformity due to the protruding edges of the
transplant during the postoperative period.
Also at the symposium, Maumenee and
Kornbleuth [35] discussed the physiopathology
of corneal transplants. During 1947 it was
unclear whether the new graft was merely a
framework for ingrowth of recipient cells, or
whether the donor stromal cells and
endothelium persisted. The importance of the
corneal endothelium in maintaining corneal
hydration was still not appreciated. Stocker’s
[36] work in 1952, brought attention to the
donor endothelium in keratoplasty. Davson in
England, Harris and Nordquist, Mishima and
Hedbys, and Dohlman, as well as Morris, all in
the USA, were to make major contributions
towards the understanding of the importance of
the corneal endothelium. Specular microscopy
was not performed until the mid-1960s, and the
longevity of the endothelium in keratoplasty
was subjected to more research, particularly by
Bourne [37]. Paufique, Sourdille, and Offret in
Paris, Billingham and Boswell in England, and
Pollack in New York, as well as Khodadoust and
Silverstein in Baltimore, were working on graft
rejection. The endothelial rejection line was
named after Ali Khodadoust [38], an
ophthalmologist still working in Connecticut
today. In the results section of this first
American Academy of Ophthalmology
Symposium on corneal transplantation, Owens
[39] discussed a study of 417 grafts of which
36.5% remained clear. The best results were
with keratoconus, of which 66% were clear and
hereditary dystrophies (59% clear). There were
no clear grafts obtained in patients who had
FECD. Max Fine, in San Francisco, was the first
corneal surgeon to perform a transplant west of
the Mississippi and to advocate keratoplasty for
FECD and aphakic bullous keratopathy [40].
The surgical techniques for keratoplasty were
slowly changing due to better instrumentation
and suture material. By 1950, Jose´ Barraquer
[41], a pioneer in keratoplasty in Barcelona,
Spain, was using donor tissue up to 6.5 mm in
diameter with direct suturing using fine silk
sutures and very sharp Grieshaber needles
(Grieshaber, Schaffhausen, Switzerland). In the
late 1950s and early 1960s, Mackensen and
Harms at the University of Tubingen, in West
Germany, initiated the use of nylon sutures.
They were among the first to change from silk
to nylon for direct appositional suturing.
Richard Troutman [42], in 1963, introduced
these sutures to the USA, along with the
microscope, for keratoplasty. In 1968, 10–0
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nylon for keratoplasty was introduced
commercially by Ethicon (Johnson & Johnson,
New Brunswick, NJ, USA).
ESTABLISHMENT OF EYE BANKS
As corneal transplantation became more
successful, the need for corneas from cadavers
increased. Eye banking began in the 1940s,
when Paton established the first eye bank in the
USA—the Eye Bank for Sight Restoration,
founded in New York in 1944. In 1961, the
Eye Bank Association of America was
established. Statistics for corneal transplants
compiled by the Eye Bank Association of
American their first year showed that
approximately 2,000 transplants were
performed in 1961. In 2005, approximately
36,000 transplants were undertaken in the
USA from tissue obtained from the Eye Bank
Association of America collaborating eye banks,
while another 9,000 corneas were sent overseas
for transplantation. In 2012, corneal tissue
supplied by US banks for keratoplasty of all
types was 68,681, a 1.6% increase from 67,590
in 2011. A total of 19,546 corneas were exported
internationally in 2012 compared with 18,307
in 2011, a 6.8% increase [43].
In the era of using cadaver corneas from
whole eyes, it was necessary to operate within
48 h of death to preserve the donor
endothelium. This was inconvenient for the
patient, the surgeon, and the operating room
staff, as well as only marginally healthy for the
corneal endothelium, which was bathed in
aging aqueous fluid. The concept of corneal
storage in artificial media was introduced by
McCarey and Kaufman [44] in the early 1970s.
They employed tissue culture media and various
enhancements to maintain the endothelium,
with antibiotics added later to prevent
infection. Almost all corneal transplants in the
USA are performed today using corneas that
have been stored at 4 C in corneal storage
media. In the UK and Europe organ culture is
the storage method of choice.
Corneal storage media have improved
continually so that corneas may now be stored
for at least a week, maintaining excellent
corneal endothelial physiology. The
endothelium continues to be an important
subject of research, as even 15 years after
keratoplasty, endothelial failure is a major
cause of graft failure [45].
In the 100-year review of the cornea, by
Laibson and Rapuano [46], published in 1996
for the 100th anniversary of the American
Academy of Ophthalmology, corneal
transplantation was considered well accepted
with a success rate of 90% for keratoconus,
FECD, and PBK, the three most important
diseases requiring keratoplasty.
There are of course several problems with
penetrating corneal transplants. The length of
time for best-corrected vision (BCVA) after PK
can be 18 months or longer because of selective
suture removal. With silk sutures knotted on
the surface, healing was usually complete
within 21 days, after which the sutures were
removed. With nylon sutures, which quickly
bury beneath the surface, the healing period for
a corneal transplant is much longer. It is now
routine for surgeons to leave interrupted and
running sutures in place for at least a year, and
if vision is good, with or without correction and
with little astigmatism, the sutures are left in
even longer. One of the problems with the
nylon suture is that it can break and breakage is
relatively unpredictable. Also, astigmatism after
corneal transplantation has been one of the
main problems leading to unsatisfactory vision,
even though the graft may be clear [18].
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DEVELOPMENT OF ENDOTHELIAL
KERATOPLASTY
The history of endothelial keratoplasty (EK)
began in 1956 when Tillett [47] published the
first description of posterior lamellar
keratoplasty (PLK). Although this used a full-
thickness large-incision, it was the first attempt
to use the inner layer of the cornea for treating
corneal diseases caused by endothelium. In the
1960s, Dr. Jose´ Barraquer [48] described a
method of EK using an anterior approach via
laser-assisted in situ keratomileusis LASIK flap.
After cutting a partial thickness flap with a
microkeratome, the posterior cornea consisting
of stroma, DM, and endothelium was trephined
and replaced with a donor graft that was
sutured in place. The flap was then replaced
and also sutured.
In 1999, Melles and colleagues [49, 50]
directed in the field to an intrastromal
approach, describing a large pocket dissection
through a sclero-corneal pocket incision that
held a donor without sutures. Their technique
of PLK avoided some of the pitfalls of full-
thickness surgery, but involved a difficult
dissection of both donor and host. One of the
major advantages, however, was the use of air
instead of sutures to initially secure the donor
tissue. Sutures have been associated with a host
of complications not limited to breakage,
infections, and, of course, the risks associated
with full-thickness grafts such as acute
glaucoma and rejection. The point sources of
tension from sutures and the alignment of full-
thickness stromal cuts are major contributors to
the unpredictable variations in both regular and
irregular astigmatism [51].
Later Melles et al. [52] started to change host
dissection using simple ‘‘descemetorhexis’’ in a
procedure known as ‘‘Descemet’s stripping
endothelial keratoplasty’’ (DSEK). Their
internal approach of removing DM from the
host left an ultrasmooth posterior surface on
which the dissected donor stromal disc could be
fixed. Gorovoy [53] used a microkeratome to
harvest the donor tissue to perform Descemet’s
stripping automated endothelial keratoplasty
(DSAEK). This was a successful surgical
procedure that yielded good results. However,
all too often, on pristine slit-lamp examination,
postoperative vision was limited from 20/30 to
20/50 for no apparent reason [54]. The interface
was usually blamed as the cause of decreased
vision. However, LASIK patients who also had
an interface, routinely achieved 20/20 or better
vision. Clearly, the tissue could be removed
more precisely in LASIK than it could be added
in DSAEK.
DSAEK has been shown to achieve faster
visual recovery, lower postoperative
astigmatism, and a lower incidence of graft
failure than PK [55]. In a comparison of PK with
DSAEK, more than 1 year after transplantation,
DSAEK had a statistically insignificant higher
rate of repeat grafting at 15 months [56].
Regardless of this, DSAEK is highly successful
and has been widely adopted. In a cohort study
of 12 patients who underwent DSAEK surgery in
one eye and PK in the other, all patients
reported higher satisfaction with the DSAEK
procedure and achieved better uncorrected
visual acuity (UCVA) and best-corrected visual
acuity (BCVA) [57].
Following the widespread adoption of
DSAEK surgery, the Melles group [58] revisited
selective DM transplantation and reported the
results of a new procedure, DM endothelial
keratoplasty (DMEK). In DMEK, the donor DM
was stripped from a corneoscleral rim and
injected into the host anterior segment, which
had been stripped of its own DM, via a 3-mm
clear corneal incision. The membrane was
unrolled using pneumatic and fluidic
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manipulations and opposed to the recipient
posterior stroma using the air bubble technique.
The initial results were encouraging; of 10 eyes
transplanted, four had BCVA of better than
20/40 1 week after surgery and 6 achieved
greater than 20/40 BCVA at week 6
postoperatively. Moreover, this simplified
technique negated the need for an automated
microkeratome to smooth a stromal graft,
allowing this technique to be accessible to a
greater number of surgeons. The Melles group
[59] subsequently presented their first 50 cases
of DMEK; of those eyes where the Descemet’s
graft adhered (n = 40, 80%), 75% achieved best
spectacle-correct visual acuity (BSCVA) of 20/25
or better within 3 months.
In December 2009, 2 months after the Melles
paper, Price et al. reported their prospective
study of 60 DMEK procedures in 56 eyes in the
United States. Their results were similar to the
Melles study; the Price group [60] reported 63%
of eyes with a BCVA of 20/25 or better and 94%
with vision of 20/40 or better at 3 months. This
was significantly better than the results
achieved with DSAEK surgery.
Initial endothelial cell counts following
DMEK are comparable with PK and DSAEK.
The Melles group reported an average
endothelial cell density of 1,850 cells/mm2 at
6 months after surgery and 1,680 cells/mm2 at
12 months [61]. The Price group [60] reported a
mean endothelial cell loss of 30% at 3 months.
These results are similar to values reported after
DSEK, DSAEK, and PK [55, 62–65]. Each
iteration of EK has brought corneal surgeons
one step closer to pure endothelial cell
transplantation and even more innovative
treatments for diseases of the endothelium.
The Melles group [66], for example, recently
reported spontaneous corneal clearing after
DMEK in a patient with a previous
permanently dislocated graft. Therefore, could
corneal clarity be achieved in the absence of a
permanent graft?
Submerged cornea using backgrounds away
(SCUBA) technique, which is a method for
preparing DMEK donor tissue, has previously
been described [67]. Separating DM while
submerged in fluid allowed for easy handling
and removed the effect of surface tension on
tear promotion. The technique was consistently
reliable, used simple instruments that were
readily available, and could be taught to eye
bank technicians.
The key technique for successful
implantation is ‘‘the Dead Sea Scrolls’’ method
[68]. This term highlighted the natural scrolling
tendency of a stroma-free DM, and the correct
orientation of the endothelial side before the
donor scroll was fixed in position with air. The
technique also included no-touch manipulation
using microjets of fluid, externally induced
eddy currents, surface tension, and air bubbles
to unroll, position, and secure the donor in the
confines of the anterior chamber. Visualization
of the donor was enhanced with trypan blue
staining. It was found that proper air
management could prevent the dislocations
that had initially been described. In addition,
the difference in curvature between the donor
and the host, that often leads to peripheral
detachments, could be easily treated by
rebubbling with air [68, 69].
Studeny et al. [70] realized that leaving a rim
of stroma in the periphery of the donor cornea
remarkably improved handling inside the eye,
whilst still providing the visual benefits of
DMEK. This was referred to as ‘‘DMEK with a
stromal rim’’. Other variations were proposed by
Price with DMAEK (DM automated endothelial
keratoplasty), and by Busin with ‘‘sickle’’ DMEK
[71–73]. Tissue was prepared using a
microkeratome and a stromal air injection (big
bubble) to harvest donor tissue and was
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successful in skilled hands [74, 75]. However, in
exchange for the ease of intraoperative
placement, this technique required an
expensive microkeratome, offered its own
challenges, and DMAEK or sickle DMEK tissue
preparation was not consistently successful.
Recently, some eye banks have experimented
with the preparation of DMEK/DMAEK donor
tissue that may help surgeons avoid the risk of
tissue loss during the stromal separation step
[43]. Today’s DMEK surgeons have that option
and may obtain eye bank-prepared tissue or
prepare the tissue themselves.
In 2013 Ether et al. describe a standardized
‘no-touch’ harvesting technique of anterior
membrane and DM grafts for use in deep
anterior lamellar keratoplasty (DALK) and
DMEK, which provides undamaged anterior
and posterior corneal grafts [76].
Regarding the presence of stromal tissue on
the DM of the donor tissue, Yoeruek et al. [74]
examined the dissection plane achieved when
pneumatic dissection is used to create the donor
graft for EK; they found no stroma attached to
the DM on either light or electron microscopy,
implying a complete separation of stroma and
DM. On the contrary, another recent, smaller
study documented residual stroma on the DM
by light microscopy after pneumatic dissection
[77]. These differences were attributed to
differences in methodology between both
studies [78]. Recently, the present authors
described a new bimanual technique for
insertion and positioning of endothelium-DM
(EDM) grafts in DMEK [79].
In a prospective, non-comparative,
consecutive, interventional case series, which
included 15 pseudophakic eyes of 15 patients
treated with DMEK (Fig. 2), a bimanual
infusion technique was used to introduce
and position donor’s EDM [79]. Partial
tamponade was achieved with 20% sulfur
fluoride (SF6). Intraocular manipulation time
of EDM grafts, rebubbling rate, and
endothelial cell density were evaluated. Six
months postoperatively, mean UCVA and
BSCVA had improved from 20/100 to 20/50,
and from 20/80 to 20/25, respectively,
(P\0.001). Six (40%) eyes had C20/20
BSCVA, and 13 (86%) eyes had C20/30
BSCVA. Mean donor cell density decreased
from 2,690 ± 302 cells/mm2 to 1,998 ± 621
cells/mm2, representing a mean cell loss of
26 ± 20% after 6 months. EDM was stripped
successfully in all cases. Mean intraocular
manipulation time of donor’s EDM (interval
between main incision closure and final EDM
positioning) was 4.10 ± 0.5 min. Intracameral
air reinjection was needed in one case (6.6%)
with a partial, peripheral graft detachment. No
episodes of immunological graft rejection were
documented [79].
A recent study showed for the first time that
leucine-rich repeat-containing G-protein
coupled receptor 5 (LGR5) is uniquely
expressed in the peripheral region of human
corneal endothelial cells and that LGR5(?) cells
have some stem/progenitor cell characteristics
[80]. Furthermore, in human corneal
endothelium, LGR5 is the target molecule and
negative feedback regulator of the Hedgehog
(HH) signaling pathway. Interestingly, the
findings of this study show that persistent
LGR5 expression maintained endothelial cell
phenotypes and inhibited mesenchymal
transformation (MT) through the Wnt
pathway. Moreover, R-spondin-1, an LGR5
ligand, dramatically accelerated corneal
endothelial cell proliferation and also
inhibited MT through the Wnt pathway. These
findings provide new insights into the
underlying homeostatic regulation of human
corneal endothelial stem/progenitor cells by
LGR5 via the HH and Wnt pathways [79].
10 Ophthalmol Ther (2014) 3:1–15
CONCLUSION
Until today, corneal endothelial disease has
been treated by tissue substitution.
Endothelial transplantation techniques have
significantly progressed during the last
10 years being DSAEK and finally DMEK their
best examples of selectivity. On the other
hand, research in drugs directed to improve
EC health is also increasing, in clinical
practice during the next few years.
Hopefully, gene therapy will pay attention to
corneal endothelial diseases in the near future.
We think this will be a great achievement in
the field of management of corneal
endothelial diseases.
Fig. 2 Pseudophakic eye with Fuchs’ endothelial corneal dystrophy treated by Descemet membrane endothelial
keratoplasty: a Preop: BSCVA: 0,05. b 24 h. postop. VA: 0,16. c 20 days postop. BSCVA: 0,9
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